Is Pacific Biosciences of California, Inc. (PACB) a good stock to buy?

Olyth's institutional analysis of PACB reveals an Altman Z-Score of -6.07 and a Piotroski F-Score of 3/9. These metrics, combined with its 5-year revenue trend ($0.16B most recent), help investors decide if PACB fits their risk profile.

What is the current P/E ratio for PACB?

As of the latest trading session, Pacific Biosciences of California, Inc. (PACB) has a trailing P/E ratio of -0.78.

Who is the CEO of Pacific Biosciences of California, Inc.?

The current Chief Executive Officer of Pacific Biosciences of California, Inc. is Christian O. Henry.

What was PACB's revenue for the last 5 years?

According to its latest income statements, Pacific Biosciences of California, Inc. reported annual revenues of $0.16B (2025), $0.15B (2024), $0.20B (2023), $0.13B (2022), $0.13B (2021) respectively.

Does PACB pay a dividend?

Pacific Biosciences of California, Inc. does not currently pay a dividend to its shareholders.

How much debt and cash flow does PACB have?

In its latest reporting period, Pacific Biosciences of California, Inc. generated $-0.11B in Free Cash Flow against a total debt load of $0.76B.

What is the Price-to-Book (P/B) ratio of Pacific Biosciences of California, Inc.?

The Price-to-Book (P/B) ratio for Pacific Biosciences of California, Inc. (PACB) is currently 80.15.

What is the Price-to-Sales (P/S) ratio of PACB?

Based on trailing twelve-month data, Pacific Biosciences of California, Inc. (PACB) trades at a Price-to-Sales (P/S) ratio of 2.68.

What is Pacific Biosciences of California, Inc.'s Return on Equity (ROE)?

Pacific Biosciences of California, Inc. (PACB) has a Return on Equity (ROE) of -1123.27%, representing its profitability relative to shareholder equity.

PACB

Pacific Biosciences of California, Inc. · Healthcare

1.42

5.97%(+0.08)

Prev. Close

1.45

2.11%(+0.03)

Pre-market

Last Updated: — ET

52W L: $0.8552W H: $2.73

$1.38

CHG+0.02 (+1.47%)

H$1.46

L$1.23

VOL94M

PACB (1h)

Company Profile

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a development and commercialization agreement with Invitae Corporation. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

Sector

Healthcare

Industry

Medical - Devices

Employees

575

IPO Date

2010-10-27

Beta

2.33

Websitewww.pacb.com↗

PACB

Financial Analysis: Pacific Biosciences of California (NASDAQ:PACB) versus DexCom (NASDAQ:DXCM)

Here's Why You Should Add PacBio Stock to Your Portfolio Now

Pacific Biosciences of California (PACB) Registers a Bigger Fall Than the Market: Important Facts to Note

PacBio Wins Basecamp Research Deal for Trillion Gene Atlas Initiative

Pacific Biosciences (PACB) Upgraded to Strong Buy: What Does It Mean for the Stock?

Basecamp Research Selects PacBio HiFi Sequencing to Power Trillion Gene Atlas Initiative